13th Apr 2016 08:39
LONDON (Alliance News) - Biomedical and healthcare technology firm NetScientific PLC on Wednesday said its PDS Biotechnology portfolio company is set to announce positive phase 1 study results for the PDS0101 immunotherapy for HPV-related cancers.
The study was carried out in cervical neoplasia subjects infected with high-risk cancer-causing strains of HPV, NetScientific said.
The phase 1 study showed PDS0101 has successfully overcome a key immunotherapy obstacle by efficiently accessing the MHC Class-1 immunological pathway.
NetScientific added it intends to invest another USD500,000 in PDS Biotechnology. To date, NetScientific has invested GBP1.8 million in the company and owns a 15% stake in PDS.
"As an early stage investor in PDS Biotechnology we look forward to continuing our support of the company as it looks to further corroborate the potential of PDS0101 in upcoming phase 2 studies in pre-cancer, cervical and head and neck cancers," said Francois Martelet, NetScientific's chief executive.
NetScientific shares were up 1.3% to 76.50 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Netscientific